This pathway is one of the mechanisms through which GLP-1R agonists are thought to provide neuroprotection in multiple in vitro and animal models of Parkinson’s and Alzheimer’s neurodegeneration (Erbil et al., 2019). This evidence concerns the gene GLP1R and Parkinson disease.